MAV/06

Product

Last mentioned: Mar 11, 2026

Timeline

  1. 30-Year Review Publication

    Comprehensive review paper summarizing three decades of data is published in a peer-reviewed journal.

  2. Barycel Launch

    GC Biopharma launches an improved version of its varicella vaccine based on the MAV/06 strain.

  3. Global Expansion

    The MAV/06-based vaccine is exported to over 30 countries and integrated into national immunization programs.

  4. Initial Development

    GC Biopharma begins the clinical application of the MAV/06 varicella strain.

Stories mentioning MAV/06 1

pharma Neutral

GC Biopharma Validates Proprietary MAV/06 Varicella Strain with 30-Year Data Review

GC Biopharma has published a comprehensive review paper detailing three decades of clinical and real-world data for its proprietary MAV/06 varicella vaccine strain. This publication underscores the long-term safety and efficacy of the strain, which has been a cornerstone of the company's global vaccine portfolio and international procurement strategy.

2 sources